Interestingly, the GLP-1R/GLP-2R dual agonist dapiglutide is being investigated in the DREAM Trial (NCT05788601) to lower body weight and low-grade inflammation in obesity
However, these rebates vary from payer to payer, from medication to medication (i.e., varying rebates would be applied to all interventions included in the analysis), and are confidential
FURTHER POTENTIAL TREATMENTS FOR OBESITY AND T2DM Beyond the GLP-1 and GIP co-agonism, multiple gut hormones are undergoing early phase clinical trials in combination with GLP-1 (as dual or triple agonists) as potential treatments for obesity and T2DM
Dose tracking journal or app: Track injection date, site, dose, and any side effects
Belmar Pharmacy compounds a variety of wellness medications